Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 54

1.

CDK6 Antagonizes p53-Induced Responses during Tumorigenesis.

Bellutti F, Tigan AS, Nebenfuehr S, Dolezal M, Zojer M, Grausenburger R, Hartenberger S, Kollmann S, Doma E, Prchal-Murphy M, Uras IZ, Höllein A, Neuberg DS, Ebert BL, Ringler A, Mueller AC, Loizou JI, Hinds PW, Vogl C, Heller G, Kubicek S, Zuber J, Malumbres M, Farlik M, Villunger A, Kollmann K, Sexl V.

Cancer Discov. 2018 Jul;8(7):884-897. doi: 10.1158/2159-8290.CD-17-0912. Epub 2018 Jun 13.

PMID:
29899063
2.

Pharmacologic inhibition of STAT5 in acute myeloid leukemia.

Wingelhofer B, Maurer B, Heyes EC, Cumaraswamy AA, Berger-Becvar A, de Araujo ED, Orlova A, Freund P, Ruge F, Park J, Tin G, Ahmar S, Lardeau CH, Sadovnik I, Bajusz D, Keserű GM, Grebien F, Kubicek S, Valent P, Gunning PT, Moriggl R.

Leukemia. 2018 May;32(5):1135-1146. doi: 10.1038/s41375-017-0005-9. Epub 2018 Feb 2.

3.

STAT5BN642H is a driver mutation for T cell neoplasia.

Pham HTT, Maurer B, Prchal-Murphy M, Grausenburger R, Grundschober E, Javaheri T, Nivarthi H, Boersma A, Kolbe T, Elabd M, Halbritter F, Pencik J, Kazemi Z, Grebien F, Hengstschläger M, Kenner L, Kubicek S, Farlik M, Bock C, Valent P, Müller M, Rülicke T, Sexl V, Moriggl R.

J Clin Invest. 2018 Jan 2;128(1):387-401. doi: 10.1172/JCI94509. Epub 2017 Dec 4.

4.

Image-based ex-vivo drug screening for patients with aggressive haematological malignancies: interim results from a single-arm, open-label, pilot study.

Snijder B, Vladimer GI, Krall N, Miura K, Schmolke AS, Kornauth C, Lopez de la Fuente O, Choi HS, van der Kouwe E, Gültekin S, Kazianka L, Bigenzahn JW, Hoermann G, Prutsch N, Merkel O, Ringler A, Sabler M, Jeryczynski G, Mayerhoefer ME, Simonitsch-Klupp I, Ocko K, Felberbauer F, Müllauer L, Prager GW, Korkmaz B, Kenner L, Sperr WR, Kralovics R, Gisslinger H, Valent P, Kubicek S, Jäger U, Staber PB, Superti-Furga G.

Lancet Haematol. 2017 Dec;4(12):e595-e606. doi: 10.1016/S2352-3026(17)30208-9. Epub 2017 Nov 15.

5.

Repair of UV-Induced DNA Damage Independent of Nucleotide Excision Repair Is Masked by MUTYH.

Mazouzi A, Battistini F, Moser SC, Ferreira da Silva J, Wiedner M, Owusu M, Lardeau CH, Ringler A, Weil B, Neesen J, Orozco M, Kubicek S, Loizou JI.

Mol Cell. 2017 Nov 16;68(4):797-807.e7. doi: 10.1016/j.molcel.2017.10.021.

PMID:
29149600
6.

First-in-human response of BCL-2 inhibitor venetoclax in T-cell prolymphocytic leukemia.

Boidol B, Kornauth C, van der Kouwe E, Prutsch N, Kazianka L, Gültekin S, Hoermann G, Mayerhoefer ME, Hopfinger G, Hauswirth A, Panny M, Aretin MB, Hilgarth B, Sperr WR, Valent P, Simonitsch-Klupp I, Moriggl R, Merkel O, Kenner L, Jäger U, Kubicek S, Staber PB.

Blood. 2017 Dec 7;130(23):2499-2503. doi: 10.1182/blood-2017-05-785683. Epub 2017 Sep 27.

PMID:
28972014
7.

A histone-mimicking interdomain linker in a multidomain protein modulates multivalent histone binding.

Kostrhon S, Kontaxis G, Kaufmann T, Schirghuber E, Kubicek S, Konrat R, Slade D.

J Biol Chem. 2017 Oct 27;292(43):17643-17657. doi: 10.1074/jbc.M117.801464. Epub 2017 Sep 1.

8.

A TRPV1-to-secretagogin regulatory axis controls pancreatic β-cell survival by modulating protein turnover.

Malenczyk K, Girach F, Szodorai E, Storm P, Segerstolpe Å, Tortoriello G, Schnell R, Mulder J, Romanov RA, Borók E, Piscitelli F, Di Marzo V, Szabó G, Sandberg R, Kubicek S, Lubec G, Hökfelt T, Wagner L, Groop L, Harkany T.

EMBO J. 2017 Jul 14;36(14):2107-2125. doi: 10.15252/embj.201695347. Epub 2017 Jun 21.

9.

A combinatorial screen of the CLOUD uncovers a synergy targeting the androgen receptor.

Licciardello MP, Ringler A, Markt P, Klepsch F, Lardeau CH, Sdelci S, Schirghuber E, Müller AC, Caldera M, Wagner A, Herzog R, Penz T, Schuster M, Boidol B, Dürnberger G, Folkvaljon Y, Stattin P, Ivanov V, Colinge J, Bock C, Kratochwill K, Menche J, Bennett KL, Kubicek S.

Nat Chem Biol. 2017 Jul;13(7):771-778. doi: 10.1038/nchembio.2382. Epub 2017 May 22.

PMID:
28530711
10.

Global survey of the immunomodulatory potential of common drugs.

Vladimer GI, Snijder B, Krall N, Bigenzahn JW, Huber KVM, Lardeau CH, Sanjiv K, Ringler A, Berglund UW, Sabler M, de la Fuente OL, Knöbl P, Kubicek S, Helleday T, Jäger U, Superti-Furga G.

Nat Chem Biol. 2017 Jun;13(6):681-690. doi: 10.1038/nchembio.2360. Epub 2017 Apr 24.

11.

TKI rotation-induced persistent deep molecular response in multi-resistant blast crisis of Ph+ CML.

Valent P, Herndlhofer S, Schneeweiß M, Boidol B, Ringler A, Kubicek S, Gleixner KV, Hoermann G, Hadzijusufovic E, Müllauer L, Sperr WR, Superti-Furga G, Mannhalter C.

Oncotarget. 2017 Apr 4;8(14):23061-23072. doi: 10.18632/oncotarget.15481.

12.

Cdk6 contributes to cytoskeletal stability in erythroid cells.

Uras IZ, Scheicher RM, Kollmann K, Glösmann M, Prchal-Murphy M, Tigan AS, Fux DA, Altamura S, Neves J, Muckenthaler MU, Bennett KL, Kubicek S, Hinds PW, von Lindern M, Sexl V.

Haematologica. 2017 Jun;102(6):995-1005. doi: 10.3324/haematol.2016.159947. Epub 2017 Mar 2.

13.

Artemisinins Target GABAA Receptor Signaling and Impair α Cell Identity.

Li J, Casteels T, Frogne T, Ingvorsen C, Honoré C, Courtney M, Huber KVM, Schmitner N, Kimmel RA, Romanov RA, Sturtzel C, Lardeau CH, Klughammer J, Farlik M, Sdelci S, Vieira A, Avolio F, Briand F, Baburin I, Májek P, Pauler FM, Penz T, Stukalov A, Gridling M, Parapatics K, Barbieux C, Berishvili E, Spittler A, Colinge J, Bennett KL, Hering S, Sulpice T, Bock C, Distel M, Harkany T, Meyer D, Superti-Furga G, Collombat P, Hecksher-Sørensen J, Kubicek S.

Cell. 2017 Jan 12;168(1-2):86-100.e15. doi: 10.1016/j.cell.2016.11.010. Epub 2016 Dec 1.

14.

DNMT3A mutations promote anthracycline resistance in acute myeloid leukemia via impaired nucleosome remodeling.

Guryanova OA, Shank K, Spitzer B, Luciani L, Koche RP, Garrett-Bakelman FE, Ganzel C, Durham BH, Mohanty A, Hoermann G, Rivera SA, Chramiec AG, Pronier E, Bastian L, Keller MD, Tovbin D, Loizou E, Weinstein AR, Gonzalez AR, Lieu YK, Rowe JM, Pastore F, McKenney AS, Krivtsov AV, Sperr WR, Cross JR, Mason CE, Tallman MS, Arcila ME, Abdel-Wahab O, Armstrong SA, Kubicek S, Staber PB, Gönen M, Paietta EM, Melnick AM, Nimer SD, Mukherjee S, Levine RL.

Nat Med. 2016 Dec;22(12):1488-1495. doi: 10.1038/nm.4210. Epub 2016 Nov 14.

15.

Heme drives hemolysis-induced susceptibility to infection via disruption of phagocyte functions.

Martins R, Maier J, Gorki AD, Huber KV, Sharif O, Starkl P, Saluzzo S, Quattrone F, Gawish R, Lakovits K, Aichinger MC, Radic-Sarikas B, Lardeau CH, Hladik A, Korosec A, Brown M, Vaahtomeri K, Duggan M, Kerjaschki D, Esterbauer H, Colinge J, Eisenbarth SC, Decker T, Bennett KL, Kubicek S, Sixt M, Superti-Furga G, Knapp S.

Nat Immunol. 2016 Dec;17(12):1361-1372. doi: 10.1038/ni.3590. Epub 2016 Oct 31.

PMID:
27798618
16.

Acquired nintedanib resistance in FGFR1-driven small cell lung cancer: role of endothelin-A receptor-activated ABCB1 expression.

Englinger B, Lötsch D, Pirker C, Mohr T, van Schoonhoven S, Boidol B, Lardeau CH, Spitzwieser M, Szabó P, Heffeter P, Lang I, Cichna-Markl M, Grasl-Kraupp B, Marian B, Grusch M, Kubicek S, Szakács G, Berger W.

Oncotarget. 2016 Aug 2;7(31):50161-50179. doi: 10.18632/oncotarget.10324.

17.

FASIL-MS: An Integrated Proteomic and Bioinformatic Workflow To Universally Quantitate In Vivo-Acetylated Positional Isomers.

Vitko D, Májek P, Schirghuber E, Kubicek S, Bennett KL.

J Proteome Res. 2016 Aug 5;15(8):2579-94. doi: 10.1021/acs.jproteome.6b00130. Epub 2016 Jul 5.

PMID:
27302567
18.

Mapping the chemical chromatin reactivation landscape identifies BRD4-TAF1 cross-talk.

Sdelci S, Lardeau CH, Tallant C, Klepsch F, Klaiber B, Bennett J, Rathert P, Schuster M, Penz T, Fedorov O, Superti-Furga G, Bock C, Zuber J, Huber KV, Knapp S, Müller S, Kubicek S.

Nat Chem Biol. 2016 Jul;12(7):504-10. doi: 10.1038/nchembio.2080. Epub 2016 May 9.

PMID:
27159579
19.

Palbociclib treatment of FLT3-ITD+ AML cells uncovers a kinase-dependent transcriptional regulation of FLT3 and PIM1 by CDK6.

Uras IZ, Walter GJ, Scheicher R, Bellutti F, Prchal-Murphy M, Tigan AS, Valent P, Heidel FH, Kubicek S, Scholl C, Fröhling S, Sexl V.

Blood. 2016 Jun 9;127(23):2890-902. doi: 10.1182/blood-2015-11-683581. Epub 2016 Apr 20.

20.

Pharmacological treats for SUMO addicts.

Licciardello MP, Kubicek S.

Pharmacol Res. 2016 May;107:390-397. doi: 10.1016/j.phrs.2016.01.004. Epub 2016 Jan 24. Review.

PMID:
26816086
21.

Single-cell transcriptomes reveal characteristic features of human pancreatic islet cell types.

Li J, Klughammer J, Farlik M, Penz T, Spittler A, Barbieux C, Berishvili E, Bock C, Kubicek S.

EMBO Rep. 2016 Feb;17(2):178-87. doi: 10.15252/embr.201540946. Epub 2015 Dec 21.

22.

Stimulating translational research: several European life science institutions put their heads together.

Bentires-Alj M, Rajan A, van Harten W, van Luenen HG, Kubicek S, Andersen JB, Saarela J, Cook SJ, Van Minnebruggen G, Roman-Roman S, Maurer C, Erler JT, Bertero MG.

Trends Mol Med. 2015 Sep;21(9):525-7. doi: 10.1016/j.molmed.2015.07.002. Epub 2015 Aug 5.

PMID:
26254816
23.

A cellular screen identifies ponatinib and pazopanib as inhibitors of necroptosis.

Fauster A, Rebsamen M, Huber KV, Bigenzahn JW, Stukalov A, Lardeau CH, Scorzoni S, Bruckner M, Gridling M, Parapatics K, Colinge J, Bennett KL, Kubicek S, Krautwald S, Linkermann A, Superti-Furga G.

Cell Death Dis. 2015 May 21;6:e1767. doi: 10.1038/cddis.2015.130.

24.

Epigenome mapping reveals distinct modes of gene regulation and widespread enhancer reprogramming by the oncogenic fusion protein EWS-FLI1.

Tomazou EM, Sheffield NC, Schmidl C, Schuster M, Schönegger A, Datlinger P, Kubicek S, Bock C, Kovar H.

Cell Rep. 2015 Feb 24;10(7):1082-95. doi: 10.1016/j.celrep.2015.01.042. Epub 2015 Feb 19.

25.

Targeting a cell state common to triple-negative breast cancers.

Muellner MK, Mair B, Ibrahim Y, Kerzendorfer C, Lechtermann H, Trefzer C, Klepsch F, Müller AC, Leitner E, Macho-Maschler S, Superti-Furga G, Bennett KL, Baselga J, Rix U, Kubicek S, Colinge J, Serra V, Nijman SM.

Mol Syst Biol. 2015 Feb 19;11(1):789. doi: 10.15252/msb.20145664.

26.

The methyltransferase Setdb2 mediates virus-induced susceptibility to bacterial superinfection.

Schliehe C, Flynn EK, Vilagos B, Richson U, Swaminanthan S, Bosnjak B, Bauer L, Kandasamy RK, Griesshammer IM, Kosack L, Schmitz F, Litvak V, Sissons J, Lercher A, Bhattacharya A, Khamina K, Trivett AL, Tessarollo L, Mesteri I, Hladik A, Merkler D, Kubicek S, Knapp S, Epstein MM, Symer DE, Aderem A, Bergthaler A.

Nat Immunol. 2015 Jan;16(1):67-74. doi: 10.1038/ni.3046. Epub 2014 Nov 24.

27.

NOTCH1 activation in breast cancer confers sensitivity to inhibition of SUMOylation.

Licciardello MP, Müllner MK, Dürnberger G, Kerzendorfer C, Boidol B, Trefzer C, Sdelci S, Berg T, Penz T, Schuster M, Bock C, Kralovics R, Superti-Furga G, Colinge J, Nijman SM, Kubicek S.

Oncogene. 2015 Jul;34(29):3780-90. doi: 10.1038/onc.2014.319. Epub 2014 Sep 29.

PMID:
25263445
28.

A strand-specific switch in noncoding transcription switches the function of a Polycomb/Trithorax response element.

Herzog VA, Lempradl A, Trupke J, Okulski H, Altmutter C, Ruge F, Boidol B, Kubicek S, Schmauss G, Aumayr K, Ruf M, Pospisilik A, Dimond A, Senergin HB, Vargas ML, Simon JA, Ringrose L.

Nat Genet. 2014 Sep;46(9):973-981. doi: 10.1038/ng.3058. Epub 2014 Aug 10.

29.

The solute carrier SLC35F2 enables YM155-mediated DNA damage toxicity.

Winter GE, Radic B, Mayor-Ruiz C, Blomen VA, Trefzer C, Kandasamy RK, Huber KVM, Gridling M, Chen D, Klampfl T, Kralovics R, Kubicek S, Fernandez-Capetillo O, Brummelkamp TR, Superti-Furga G.

Nat Chem Biol. 2014 Sep;10(9):768-773. doi: 10.1038/nchembio.1590. Epub 2014 Jul 27.

30.

Quantitative-proteomic comparison of alpha and Beta cells to uncover novel targets for lineage reprogramming.

Choudhary A, Hu He K, Mertins P, Udeshi ND, Dančík V, Fomina-Yadlin D, Kubicek S, Clemons PA, Schreiber SL, Carr SA, Wagner BK.

PLoS One. 2014 Apr 23;9(4):e95194. doi: 10.1371/journal.pone.0095194. eCollection 2014.

31.

Exploiting epigenetic vulnerabilities for cancer therapeutics.

Mair B, Kubicek S, Nijman SM.

Trends Pharmacol Sci. 2014 Mar;35(3):136-45. doi: 10.1016/j.tips.2014.01.001. Epub 2014 Feb 12. Review.

PMID:
24529765
32.

Connecting Small Molecules with Similar Assay Performance Profiles Leads to New Biological Hypotheses.

Dančík V, Carrel H, Bodycombe NE, Seiler KP, Fomina-Yadlin D, Kubicek ST, Hartwell K, Shamji AF, Wagner BK, Clemons PA.

J Biomol Screen. 2014 Jun;19(5):771-81. doi: 10.1177/1087057113520226. Epub 2014 Jan 24.

33.

PAK-dependent STAT5 serine phosphorylation is required for BCR-ABL-induced leukemogenesis.

Berger A, Hoelbl-Kovacic A, Bourgeais J, Hoefling L, Warsch W, Grundschober E, Uras IZ, Menzl I, Putz EM, Hoermann G, Schuster C, Fajmann S, Leitner E, Kubicek S, Moriggl R, Gouilleux F, Sexl V.

Leukemia. 2014 Mar;28(3):629-41. doi: 10.1038/leu.2013.351. Epub 2013 Nov 22.

34.

A small-molecule probe of the histone methyltransferase G9a induces cellular senescence in pancreatic adenocarcinoma.

Yuan Y, Wang Q, Paulk J, Kubicek S, Kemp MM, Adams DJ, Shamji AF, Wagner BK, Schreiber SL.

ACS Chem Biol. 2012 Jul 20;7(7):1152-7. doi: 10.1021/cb300139y. Epub 2012 Apr 30.

35.

Pdx1 is post-translationally modified in vivo and serine 61 is the principal site of phosphorylation.

Frogne T, Sylvestersen KB, Kubicek S, Nielsen ML, Hecksher-Sørensen J.

PLoS One. 2012;7(4):e35233. doi: 10.1371/journal.pone.0035233. Epub 2012 Apr 11.

36.

Chromatin-targeting small molecules cause class-specific transcriptional changes in pancreatic endocrine cells.

Kubicek S, Gilbert JC, Fomina-Yadlin D, Gitlin AD, Yuan Y, Wagner FF, Holson EB, Luo T, Lewis TA, Taylor B, Gupta S, Shamji AF, Wagner BK, Clemons PA, Schreiber SL.

Proc Natl Acad Sci U S A. 2012 Apr 3;109(14):5364-9. doi: 10.1073/pnas.1201079109. Epub 2012 Mar 20.

37.

GW8510 increases insulin expression in pancreatic alpha cells through activation of p53 transcriptional activity.

Fomina-Yadlin D, Kubicek S, Vetere A, He KH, Schreiber SL, Wagner BK.

PLoS One. 2012;7(1):e28808. doi: 10.1371/journal.pone.0028808. Epub 2012 Jan 5. Erratum in: PLoS One. 2012;7(3). doi: 10.1371/annotation/c41ac082-32ac-4837-b4ed-9fd8ad91c1e0. He, Kaihui Hu [corrected to He, Kai Hui Hu].

38.

An integrated chemical biology approach identifies specific vulnerability of Ewing's sarcoma to combined inhibition of Aurora kinases A and B.

Winter GE, Rix U, Lissat A, Stukalov A, Müllner MK, Bennett KL, Colinge J, Nijman SM, Kubicek S, Kovar H, Kontny U, Superti-Furga G.

Mol Cancer Ther. 2011 Oct;10(10):1846-56. doi: 10.1158/1535-7163.MCT-11-0100. Epub 2011 Jul 18.

39.

A selective inhibitor and probe of the cellular functions of Jumonji C domain-containing histone demethylases.

Luo X, Liu Y, Kubicek S, Myllyharju J, Tumber A, Ng S, Che KH, Podoll J, Heightman TD, Oppermann U, Schreiber SL, Wang X.

J Am Chem Soc. 2011 Jun 22;133(24):9451-6. doi: 10.1021/ja201597b. Epub 2011 May 31.

40.

Reduced histone biosynthesis and chromatin changes arising from a damage signal at telomeres.

O'Sullivan RJ, Kubicek S, Schreiber SL, Karlseder J.

Nat Struct Mol Biol. 2010 Oct;17(10):1218-25. doi: 10.1038/nsmb.1897. Epub 2010 Oct 3.

41.

Small-molecule inducers of insulin expression in pancreatic alpha-cells.

Fomina-Yadlin D, Kubicek S, Walpita D, Dancik V, Hecksher-Sørensen J, Bittker JA, Sharifnia T, Shamji A, Clemons PA, Wagner BK, Schreiber SL.

Proc Natl Acad Sci U S A. 2010 Aug 24;107(34):15099-104. doi: 10.1073/pnas.1010018107. Epub 2010 Aug 9.

42.

A chromatin-wide transition to H4K20 monomethylation impairs genome integrity and programmed DNA rearrangements in the mouse.

Schotta G, Sengupta R, Kubicek S, Malin S, Kauer M, Callén E, Celeste A, Pagani M, Opravil S, De La Rosa-Velazquez IA, Espejo A, Bedford MT, Nussenzweig A, Busslinger M, Jenuwein T.

Genes Dev. 2008 Aug 1;22(15):2048-61. doi: 10.1101/gad.476008.

43.

Heterochromatin formation in Drosophila is initiated through active removal of H3K4 methylation by the LSD1 homolog SU(VAR)3-3.

Rudolph T, Yonezawa M, Lein S, Heidrich K, Kubicek S, Schäfer C, Phalke S, Walther M, Schmidt A, Jenuwein T, Reuter G.

Mol Cell. 2007 Apr 13;26(1):103-15.

44.

Reversal of H3K9me2 by a small-molecule inhibitor for the G9a histone methyltransferase.

Kubicek S, O'Sullivan RJ, August EM, Hickey ER, Zhang Q, Teodoro ML, Rea S, Mechtler K, Kowalski JA, Homon CA, Kelly TA, Jenuwein T.

Mol Cell. 2007 Feb 9;25(3):473-81.

45.

Repression of p53 activity by Smyd2-mediated methylation.

Huang J, Perez-Burgos L, Placek BJ, Sengupta R, Richter M, Dorsey JA, Kubicek S, Opravil S, Jenuwein T, Berger SL.

Nature. 2006 Nov 30;444(7119):629-32. Epub 2006 Nov 15.

PMID:
17108971
46.

Recruitment of PRC1 function at the initiation of X inactivation independent of PRC2 and silencing.

Schoeftner S, Sengupta AK, Kubicek S, Mechtler K, Spahn L, Koseki H, Jenuwein T, Wutz A.

EMBO J. 2006 Jul 12;25(13):3110-22. Epub 2006 Jun 8.

47.

Jmjd2b antagonizes H3K9 trimethylation at pericentric heterochromatin in mammalian cells.

Fodor BD, Kubicek S, Yonezawa M, O'Sullivan RJ, Sengupta R, Perez-Burgos L, Opravil S, Mechtler K, Schotta G, Jenuwein T.

Genes Dev. 2006 Jun 15;20(12):1557-62. Epub 2006 May 31.

48.

The role of histone modifications in epigenetic transitions during normal and perturbed development.

Kubicek S, Schotta G, Lachner M, Sengupta R, Kohlmaier A, Perez-Burgos L, Linderson Y, Martens JH, O'Sullivan RJ, Fodor BD, Yonezawa M, Peters AH, Jenuwein T.

Ernst Schering Res Found Workshop. 2006;(57):1-27. Review.

PMID:
16568946
49.

A crack in histone lysine methylation.

Kubicek S, Jenuwein T.

Cell. 2004 Dec 29;119(7):903-6. Review.

50.

Su(var) genes regulate the balance between euchromatin and heterochromatin in Drosophila.

Ebert A, Schotta G, Lein S, Kubicek S, Krauss V, Jenuwein T, Reuter G.

Genes Dev. 2004 Dec 1;18(23):2973-83.

Supplemental Content

Loading ...
Support Center